Notable 52-Week Highs and Lows 8/5: (MRK) (MTZ) (AZN) High; (CPSI) (BBRG) (APRI) Low

August 5, 2016 3:18 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

52-Week High:
  • Merck (NYSE: MRK) $62.98. Merck gaining as Bristol-Myers Squibb's CheckMate -026, phase 3 study of Opdivo for treatment of patients with NSCLC missed its primary endpoint.

  • MasTec (NYSE: MTZ) $29.30. MasTec reported Q2 EPS of $0.36, versus the analyst estimate of $0.23. Revenue for the quarter came in at $1.23 billion versus the consensus estimate of $1.16 billion. MasTec sees FY2016 EPS of $1.57, versus the consensus of $1.41.

  • AstraZeneca PLC (NYSE: AZN) $35.04. AstraZeneca shares gained early on Bristol-Myers Squibb news today.

  • AMN Healthcare Services (NYSE: AHS) $44.99. AMN Healthcare Services reported Q2 EPS of $0.61, versus the analyst estimate of $0.53. Revenue for the quarter came in at $473.7 million versus the consensus estimate of $455.14 million. AMN Healthcare Services sees Q3 2016 revenue of $466-472 million, versus the consensus of $466.2 million.
52-Week Low:
  • Computer Programs & Systems (Nasdaq: CPSI) $26.01. Computer Programs & Systems reported Q2 EPS of $0.48, versus the analyst estimate of $0.79. Revenue for the quarter came in at $68.4 million versus the consensus estimate of $74.35 million.

  • Bravo Brio Restaurant (Nasdaq: BBRG) $5.07. Bravo Brio Restaurant continuing lower following Q2 results on Wednesday night.

  • Apricus Biosciences (Nasdaq: APRI) $0.28. Apricus Biosciences reported Q2 EPS of ($0.05), versus the analyst estimate of ($0.08). Revenue for the quarter came in at $500 thousand versus the consensus estimate of $1.52 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Add Your Comment